Apple Tree Partners overview
Stories about Apple Tree Partners
Chinook Therapeutics secures $86 mln in Series A financing
Chinook Therapeutics, a Vancouver-based developer of precision medicines for kidney disease, has raised about $86 million (US$65 million) in a Series A financing. U.S. life sciences venture capital firm Versant Ventures led the round, with participation from Apple Tree Partners and Samsara BioCapital. Chinook was incubated through Versant's Inception Sciences and seeded by Versant and Apple Tree. Chinook's technology leverages single-cell RNA sequencing, human-derived organoids and new translational models to develop therapeutics with novel mechanisms of action against kidney disease pathways. Led by President and CEO Eric Dobmeier, the company will use the funds raised to advance several programs into clinical trials by 2021.
Apple Tree Partners announces promotions
New York-based Apple Tree Partners, a life sciences venture firm, has made a number of promotions. Dr. Sam Hall and Aaron Kantoff are now partners; Dr. Christine Borowski has become a principal; and Dr. Jernej Godec and Dr. Chris Cain have become senior associates.
Stoke Therapeutics hauls in $40 mln Series A
Bedford, Massachusetts-based Stoke Therapeutics Inc, which works to increase gene expression to treat diseases caused by genetic insufficiency, has raised $40 million in Series A financing. Apple Tree Partners led the round.
Elstar Therapeutics locks in $39 mln Series A
Cambridge, Massachusetts-based Elstar Therapeutics, a provider of precision cancer immunotherapy, has raised $39 million in Series A financing. The investor was Apple Tree Partners.
Syntimmune gathers $50 mln Series B in Apple Tree-led round
Waltham, Massachusetts and New York City-based Syntimmune Inc, a biotech company, has secured $50 million in Series B financing. Apple Tree Partners led the round.
VC-backed CleanSlate Centers appoints new president/CEO
CleanSlate Centers, a network of outpatient addiction treatment centers, has promoted Gregory C. Marotta to president and CEO. Previously, Marotta was chief operating officer of the company. CleanSlate is backed by healthcare-focused venture firm Apple Tree Partners.
Corvidia Therapeutics raises $26 mln in Series A funding
Corvidia Therapeutics, a biotechnology company developing cardiovascular therapies, raised $26 million in a Series A financing round co-led by Apple Tree Partners and existing backer Sofinnova Partners. In conjunction with the financing, Seth Harrison, managing partner at Apple Tree, and Adrien Lemoine of drugmaker AstraZeneca, will join Corvidia’s board.
Cure Forward picks up $15 mln from Apple Tree Partners
Newly launched patient activation company Cure Forward has raised $15 million in Series A funding. The investor was Apple Tree Partners.
Apple Tree Partners contact information
Offices
230 Park Avenue, Suite 2800, New York, 10169, United StatesContacts
| Name | Job title | Location | |
|---|---|---|---|
 Mr. William Engels | Job titleCFO | LocationNew York, United States | Email  ----------- |
| Mr. Seth L. Harrison | Job titleFounder and Managing Partner | LocationNew York, United States | Email --------- |
| Ms. Anna Batarina | Job titlePartner | LocationNew York, United States | Email ------- |
| Dr. Victor Rusu | Job titleAssociate | LocationNew York, United States | Email ------- |
Apple Tree Partners funds managed
Closed funds: 3
| Fund | Fund size | Close date | Strategy |
|---|---|---|---|
Fund size ---------- | Close dateNov 2013 | Strategy -------- | |
Fund size ------ | Close dateMay 2008 | Strategy --------- | |
Fund size ----- | Close date- | Strategy -------- | |
Stories that mention Apple Tree Partners
Nereid Therapeutics pulls in $50m Series A
Cambridge, Massachusetts-based Nereid Therapeutics, a newly launched drug developer, has raised $50 million in Series A funding.
Chinook Therapeutics bags $106m in latest financing
Chinook Therapeutics, a Vancouver, British Columbia-based developer of precision medicines for kidney disease, has raised US$106 million in financing.
Nine Square Therapeutics nets $50m Series A
San Francisco-based Nine Square Therapeutics, a developer of new treatments for movement disorders, has raised $50 million in Series A funding.
VC-backed Chinook Therapeutics to merge with Aduro Biotech
Chinook Therapeutics, a Vancouver-based developer of precision medicines for kidney disease, has agreed to merge with Aduro Biotech.
Limelight Bio snags $75 mln
Philadelphia and Cambridge, Massachusetts-based Limelight Bio, a biopharmaceutical company developing novel gene therapies, has raised $75 million in financing.
Chinook Therapeutics snags Series A
Chinook Therapeutics has raised US$65 million in Series A financing. Versant Ventures led the round with participation from Apple Tree Partners and Samsara BioCapital. Based in Seattle and Vancouver, British Columbia, Chinook is a developer of precision medicines for kidney diseases.
VC-backed Akero Therapeutics debuts IPO
Akero Therapeutics Inc, a biotech firm, has raised about $92 million for its IPO after pricing its 5.75 million shares at $16 per share. The stock began trading June 20, 2019 on the NASDAQ under the ticker symbol "AKRO." J.P. Morgan Securities LLC, Jefferies LLC and Evercore Group L.L.C. are the lead underwriters. Akero's pre-IPO investors included Janus Henderson Investors, Redmile Group, Boxer Capital of Tavistock Group, Cormorant Asset Management, BVF Partners, Rock Springs Capital, LifeSci Venture Partners, Apple Tree Partners, Atlas Venture, venBio Partners and Versant Ventures.